Aditxt, Inc. (NASDAQ: ADTX) Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference September 11th-13th, 2023
September 08 2023 - 7:05AM
Business Wire
Aditxt Chairman, Co-Founder, and Chief Executive Officer Amro
Albanna will deliver the company presentation on September 13th at
4:30 p.m. EST.
Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a
global innovation company focused on developing and commercializing
technologies that monitor and modulate the immune system, today
announced that the Aditxt management team will participate in the
H.C. Wainwright 25th Annual Global Investment Conference being held
September 11th -13th, 2023, in New York City. The in-person venue
for the event is the Lotte New York Palace Hotel in New York City
located at 455 Madison Avenue. Virtual participation will be staged
simultaneously with over 550 company presentations scheduled as
live feeds or available on-demand.
Aditxt Chairman, Co-Founder, and Chief Executive Officer Amro
Albanna will deliver the company presentation September 13th, from
4:30 p.m. to 5:00 p.m. EDT. If you are an institutional investor,
and would like to listen to the Company’s presentation, please
register here. Over 550 corporate presentations and panels are
available during September 11th -13th, 2023.
To schedule a one-on-one meeting with the Aditxt management
team, please contact your conference representative.
H.C. Wainwright 25th Annual Global Investment Conference
Date: September 11th to 13th, 2023 Aditxt Presentation
time and date: September 13, 2023, from 4:30 p.m. to 5:00 p.m.
Speaker: Amro Albanna, Chairman, Co-Founder, and Chief
Executive Officer, Aditxt, Inc. Location: Virtual attendees link
here. In-person: Lotte New York Palace Hotel, 455 Madison Ave, New
York City.
About Aditxt, Inc.
Aditxt, Inc.® (NASDAQ: ADTX) a global innovation company focused
on discovering and developing precision medicine innovations and
deploying them into high-performing businesses. Headquartered in
Richmond, Virginia, with operations in Mountain View, California,
and Melville, New York. Aditxt’s mission of “Making Promising
Innovations Possible, Together” is defined by our growing ecosystem
of research institutions, global industry partners, and
shareholders who inform and inspire our mission. Aditxt’s diverse
innovation portfolio includes: Adimune™, Inc., developing and
designing a new class of therapeutics for retraining the immune
system to address organ rejection, autoimmunity, and allergies;
Adivir™, Inc., focused on identifying, developing and
commercializing new ways to treat infectious diseases; and
Pearsanta™, Inc., offering convenient, rapid, personalized, and
high-quality lab testing —anytime and anywhere at their CLIA
certified and CAP accredited clinical laboratory based in Richmond,
VA.
For more information, visit the Company’s websites at
www.Aditxt.com, www.Adimune.com, and www.Pearsanta.com. Follow us
on LinkedIn for the latest company news.
About H.C. Wainwright & Co.
H.C. Wainwright is a full‐service investment bank dedicated to
providing corporate finance, strategic advisory and related
services to public and private companies across multiple sectors
and regions. H.C. Wainwright & Co. also provides research and
sales and trading services to institutional investors. According to
Sagient Research Systems, H.C. Wainwright’s team is ranked as the
#1 Placement Agent in terms of aggregate CMPO (confidentially
marketed public offering), RD (registered direct offering) and PIPE
(private investment in public equity) executed cumulatively since
1998. For more information visit H.C. Wainwright & Co. on the
web at www.hcwco.com
Forward-Looking Statements
Certain statements in this press release constitute
"forward-looking statements" within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company's intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company's ongoing and planned product and business development;
the Company’s ability to finance and execute on its strategic
M&A initiatives; the Company’s ability obtain the necessary
funding and partner to commence clinical trials; the Company's
intellectual property position; the Company's ability to develop
commercial functions; expectations regarding product launch and
revenue; the Company's results of operations, cash needs, spending,
financial condition, liquidity, prospects, growth and strategies;
the Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled "Risk Factors" in the Company's most recent Annual
Report on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company's other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230908812662/en/
Media and Investor Relations Contact: ir@aditxt.com
http://www.aditxt.com/
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024